AU2025204785A1 — Methods for treating Arenaviridae and Coronaviridae virus infections
Assigned to Gilead Sciences Inc · Expires 2025-07-17 · 1y expired
What this patent protects
#$%^&*AU2025204785A120250717.pdf##### ABSTRACT OF THE DISCLOSURE Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: , wherein the 1’ position of the nucleoside sugar is sub…
USPTO Abstract
#$%^&*AU2025204785A120250717.pdf##### ABSTRACT OF THE DISCLOSURE Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: , wherein the 1’ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections. ABSTRACT OF THE DISCLOSURE Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: R R¹ R N O N O N R R¹¹¹ RR R¹ R³ R² , wherein the l' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections. 20 25 20 47 85 25 J un 2 02 5 J u n 2 0 2 5 A B S T R A C T O F T H E D I S C L O S U R E P r o v i d e d a r e m e t h o d s f o r t r e a t i n g A r e n a v i r i d a e a n d C o r o n a v i r i d a e v i r u s i n f e c t i o n s b y a d m i n i s t e r i n g n u c l e o s i d e s a n d p r o d r u g s t h e r e o f , o f F o r m u l a I : R 2 0 2 5 2 0 4 7 8 5 2 5 R ¹ R N O N O N R R R R ¹ R ³ R ² , w h e r e i n t h e l ' p o s i t i o n o f t h e n u c l e o s i d e s u g a r i s s u b s t i t u t e d . T h e c o m p o u n d s , c o m p o s i t i o n s , a n d m e t h o d s p r o v i d e d a r e p a r t i c u l a r l y u s e f u l f o r t h e t r e a t m e n t o f L a s s a v i r u s a n d J u n i n v i r u s i n f e c t i o n s .
Drugs covered by this patent
- Veklury (remdesivir) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.